Investors in Tech

ALTER EQUITY was the first French management company to pioneer an investment model in companies whose activities have a positive impact on people or nature, and whose management practices align with global responsibility. Our funds seek to provide attractive returns to subscribers while mitigating risks, symbolized by the 3Ps in our name: People, Planet, Profit. IMPACT AT TWO LEVELS: The companies in which ALTER EQUITY3P II invests are characterized by their activities, which address major social or environmental issues, often aligned with the UN Sustainable Development Goals ("SDGs"). Moreover, these companies demonstrate commitment to advancing social and environmental responsibility in their business operations through dedicated management practices.

We are one of the top French leaders in seed and venture capital, with €150m under management. Over the last 30 years, we have invested in 550 companies, 27 of which have gone public. Currently, we manage a portfolio of 60 active companies. Our dedicated team of 16 people, based in Lyon and Paris, is committed to supporting innovative ventures and driving their success.

V-Sharp Venture Studio is a venture capital company focused on early stage investments in Central and Eastern Europe. V-Sharp Venture Studio is an experienced investment group focusing on early-stage investments in logistics, e-commerce, and fintech, providing strategic guidance and support to founders.

Reference Capital is a privately held advisory firm dedicated to researching and investing in disruptive technologies which will transform the world we live in. Our team is composed of seasoned VC investors and family office managers primarily based in Geneva, Switzerland with presence in London, New York, Seattle, Tel Aviv, and Dubai. Reference Capital has built the ecosystem needed to find, track and access best-in-class Venture Funds that will drive outperformance for our clients. We provide investment advisory services to institutional investors, including some of the most influential industrial families, foundations, pensions, private clients, corporate and government entities.

At KickAss Capital, we invest in extraordinary entrepreneurs with unique technologies that will define the next era of innovation. We go in at proof-of-concept stage with cash – $200k-$2M – and our support and extensive network.

We are a Venture Capital firm, shaping the future of commerce. At SPRING, we invest in tech enablers and B2B companies that provide innovative solutions to retailers and brands, including PoS management, in-store analytics, adtech, omnichannel solutions, payment, CRM, HR, and logistics. Additionally, we focus on new models of distribution such as social commerce, DNVB, ONVB, and marketplaces. Our investment approach relies on strong relationships with over 50 European (E-)Retailers, helping to drive the sales development of our portfolio companies.

Sagitta Ventures´investment mandate primarily focus on healthcare, technology, and B2B companies. Sagitta has a clear investment strategy focused on scale-ups as well as more mature companies. Sagitta has the flexibility to pursue attractive transactions across all maturity stages – early stage to mature companies.

Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target the world's most urgent medical needs. Ω is the last letter of the Greek alphabet. Our investment process starts by focusing on the end goal – delivering impactful medicines to patients. We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others. Early seed or late stage public financing. Large markets or rare diseases. Established targets or novel technologies.

At Lauxera Capital Partners, we are an independent, international asset management company focused on healthcare. Our expertise lies in growth equity investments, particularly in commercial-stage medical devices, digital health, life sciences tools, and healthcare data companies. Led by entrepreneurial company builders and seasoned healthcare investors with extensive experience across international markets, we empower European healthtech entrepreneurs to realize the growth potential of their innovations.

At NewAlpha Asset Management, we provide qualified investors with exclusive access to the most innovative and dynamic firms in the financial industry through a comprehensive range of products and services. Acting on behalf of our clients, we select, finance, and support innovative entrepreneurial projects primarily in asset management, as well as related sectors such as financial technologies and services for investment managers. As Europe's leading specialist in emerging manager seeding for institutional investors, we have established over 70 strategic partnerships and invested more than 1.5 billion euros in French and international investment management boutiques. Recognized as one of the world's most active allocators in this space, we have allocated over $500 million through 18 partnerships since 2011. NewAlpha Asset Management operates under the regulatory oversight of the Autorité des Marchés Financiers (AMF) and is a subsidiary of La Française Group and MACIF.

Why we are unique: Emerald brings open innovation and venture capital together in unparalleled fashion, with 20+ years of experience in investing in the sustainable industrial transformation. What we do: We empower corporates to successfully innovate and collaborate with start-ups, and to transition their businesses to a more sustainable future. We have over 50 large corporations as investors and partners in open innovation. How we do it: We invest in early and expansion stage start-ups globally, while being locally positioned in Europe, North America and Asia with a team of specialists from 15+ countries. Our sectors: energy, water & wastewater, food and agriculture, mobility & urbanization, materials & packaging, industrial IT About Emerald: Emerald is a globally recognized venture capital firm founded in 2000, that manages and advises assets of over €1 billion from its offices in Zurich, Toronto and Singapore.

Novo Holdings is a holding company specializing in life science investor with a focus on creating long-term value.Novo Holdings is a world-leading life science, improving health, sustainability, and generating attractive returns. As the holding and investment company of the Novo Nordisk Foundation,